Iberdomide combined with standard therapies showed a statistically significant improvement in minimal residual disease (MRD) ...

Iberdomide is a member of a new drug class in myeloma known as CELMoD agents, which build on the established platform of ...

Iberdomide, which is being positioned as a successor to Revlimid, will continue in EXCALIBER-RRMM as the study progresses to ...

US pharma major Bristol Myers Squibb has announced that the Phase III EXCALIBER-RRMM study evaluating iberdomide, an ...

An FDA AdCom voted for a new intermediate endpoint of MRD for accelerated approvals in multiple myeloma in 2024.

Amphista Therapeutics discloses first details of its TEAD Targeted Glue™ program and unveils new mechanism of action for TEAD degradation via FBXO22 First disclosure of a novel mechanism of action for ...

The $30 million Series A-3 financing consists of a $24 million first close completed in August 2024 and a $6 million second close completed in August 2025. In addition, SEED has received close to $60 ...

TRIMTECH Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively degrade protein ...

Bristol Myers Squibb (NYSE: BMY) today announced that the Phase 3 EXCALIBER-RRMM study evaluating iberdomide, an investigational cereblon E3 ligase modulator (CELMoD™), combined with standard ...

The EXCALIBER-RRMM study evaluated the efficacy and safety of iberdomide, an investigational cereblon E3 ligase modulator, in combination with dexamethasone and daratumumab in adults with RRMM.

Angelman syndrome (AS) is a rare neurodevelopmental disorder caused by the loss of function of the maternally inherited ...

The firm is betting on pairing KTX-1001 with BMS's mezigdomide and Onyx's Kyprolis in a crowded, competitive field.